New drug duo aims to outperform chemo in ovarian cancer

NCT ID NCT07684612

Not yet recruiting Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This phase 3 trial tests whether a new drug called mocertatug rezetecan (Mo-Rez) combined with bevacizumab works better than standard chemotherapy plus bevacizumab for women with platinum-sensitive ovarian cancer. The study includes about 690 participants whose cancer has returned after initial treatment. Researchers will measure how long the cancer stays under control and whether the new combination helps women live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mocertatug rezetecan (Mo-Rez) plus bevacizumab
What this could lead to: If it works, this could offer a new, more effective treatment option for women with platinum-sensitive ovarian cancer, potentially shrinking tumors and extending life.
What could go wrong: This is an early-phase 3 trial, so results are not guaranteed. The new drug may cause unexpected side effects or not work better than standard chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma ovarian neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN NEOPLASMS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.